lymphatic leakage

  • 文章类型: Journal Article
    观察铜绿假单胞菌甘露糖敏感血凝素(PA-MSHA)对根治性膀胱切除术(RC)患者预后和淋巴漏发生率的影响。
    本研究纳入2013-2022年在兰州大学第二医院行RC的129例患者。将他们分为43例接受PA-MSHA治疗的患者和86例对照组。应用治疗加权的逆概率(IPTW)来减少潜在的选择偏差。采用Kaplan-Meier法和Cox回归分析PA-MSHA对患者生存率及术后淋巴漏发生率的影响。
    与对照组相比,PA-MSHA组表现出改善的总体生存率(OS)和癌症特异性生存率(CSS)。PA-MSHA组的3年和5年总生存率(OS)分别为69.1%和53.2%,分别,对照组分别为55.6%和45.3%(Log-rank=3.218,P=0.072)。PA-MSHA组的3年和5年癌症特异性生存率(CSS)分别为73.3%和56.5%,分别,对照组分别为58.0%和47.3%(Log-rank=3.218,P=0.072)。此外,PA-MSHA组的3年和5年无进展生存率(PFS)分别为74.4%和56.8%,分别,对照组分别为57.1%和52.2%(Log-rank=2.016,P=0.156)。多因素Cox回归分析提示淋巴结转移和远处转移是患者预后不良的因素,而使用PA-MSHA可以改善患者的OS(HR:0.547,95CI:0.304-0.983,P=0.044),PFS(HR:0.469,95CI:0.229-0.959,P=0.038)和CSS(HR:0.484,95CI:0.257-0.908,P=0.024)。在IPTW调整后的队列中观察到相同的趋势。尽管术后淋巴漏的发生率没有显着差异[18.6%(8/35)与15.1%(84.9%),P=0.613]和盆腔引流量[470(440)mlvs.462.5(430)ml,P=0.814]PA-MSHA组与对照组,PA-MSHA可缩短引流管的中位保留时间(7.0dvs9.0d)(P=0.021)。
    PA-MSHA可以改善OS患者的根治性膀胱切除术,PFS,CSS,缩短盆腔引流管留置时间。
    UNASSIGNED: To observe the effect of Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) on the prognosis and the incidence of lymphatic leakage in patients undergoing radical cystectomy (RC).
    UNASSIGNED: A total of 129 patients who underwent RC in Lanzhou University Second Hospital from 2013 to 2022 were enrolled in this study. They were divided into 43 patients treated with PA-MSHA and 86 patients in the control group. Inverse probability of treatment weighting (IPTW) was applied to reduce potential selection bias. Kaplan-Meier method and Cox regression analysis were used to analyze the effect of PA-MSHA on the survival of patients and the incidence of postoperative lymphatic leakage.
    UNASSIGNED: The PA-MSHA group exhibited improved overall survival (OS) and cancer-specific survival (CSS) rates compared to the control group. The 3-year and 5-year overall survival (OS) rates for the PA-MSHA group were 69.1% and 53.2%, respectively, compared to 55.6% and 45.3% for the control group (Log-rank=3.218, P=0.072). The 3-year and 5-year cancer-specific survival (CSS) rates for the PA-MSHA group were 73.3% and 56.5%, respectively, compared to 58.0% and 47.3% for the control group (Log-rank=3.218, P=0.072). Additionally, the 3-year and 5-year progression-free survival (PFS) rates for the PA-MSHA group were 74.4% and 56.8%, respectively, compared to 57.1% and 52.2% for the control group (Log-rank=2.016, P=0.156). Multivariate Cox regression analysis indicates that lymph node metastasis and distant metastasis are poor prognostic factors for patients, while the use of PA-MSHA can improve patients\' OS (HR: 0.547, 95%CI: 0.304-0.983, P=0.044), PFS (HR: 0.469, 95%CI: 0.229-0.959, P=0.038) and CSS (HR: 0.484, 95%CI: 0.257-0.908, P=0.024). The same trend was observed in the cohort After IPTW adjustment. Although there was no significant difference in the incidence of postoperative lymphatic leakage [18.6% (8/35) vs. 15.1% (84.9%), P=0.613] and pelvic drainage volume [470 (440) ml vs. 462.5 (430) ml, P=0.814] between PA-MSHA group and control group, PA-MSHA could shorten the median retention time of drainage tube (7.0 d vs 9.0 d) (P=0.021).
    UNASSIGNED: PA-MSHA may improve radical cystectomy in patients with OS, PFS, and CSS, shorten the pelvic drainage tube retention time.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:淋巴漏是神经母细胞瘤术后并发症之一。目的总结淋巴漏的临床特点及危险因素,努力寻找有效的防治措施。
    方法:一项回顾性研究包括186例腹部神经母细胞瘤患儿,其中淋巴漏患儿32例,非淋巴漏患儿154例。临床信息,手术数据,术后腹腔引流,收集并分析两组患者的淋巴漏治疗情况及预后。
    结果:该队列中淋巴漏的发生率为14%(32名儿童)。通过对淋巴漏组与非淋巴漏组的单因素分析,我们发现淋巴渗漏增加了并发症,延长了腹腔引流和住院的时间,术后化疗延迟(p<0.05)。在这个队列中,中位随访时间为46(95%CI:44~48)个月.7名儿童的随访数据部分缺失。147名儿童幸存下来,其中23例肿瘤复发(5例患儿在手术区复发)。37名儿童死亡,其中32例肿瘤复发(9例患儿在手术区复发)。在单变量分析中,淋巴漏组和非淋巴漏组总生存率(p=0.21)和无事件生存率(p=0.057)差异无统计学意义。而淋巴漏组的局部进展3年累积发生率较高(p=0.015)。然而,通过多变量分析,我们发现淋巴渗漏并不影响无事件生存率,神经母细胞瘤患儿的总体生存率和局部进展累积发生率.切除5个或5个以上淋巴区域是神经母细胞瘤术后淋巴漏的独立危险因素。32例淋巴漏患儿均经保守治疗治愈,未手术治疗。其中,75%(24/32)的儿童通过无脂饮食或观察治愈,25%(8/32)的儿童通过全胃肠外营养治愈。完全肠外营养组诊断时的中位引流输出高于非完全肠外营养组(p<0.001)。截止值为17.2ml/kg/天。
    结论:淋巴漏不影响神经母细胞瘤患儿的预后,但淋巴漏引起的长期引流仍将对术后并发症和后续治疗产生不利影响,这需要注意和积极的治疗措施。对5个或5个以上淋巴区域切除的患儿应给予更多的关注,肿瘤切除后应积极寻找损伤的淋巴管并结扎,以减少术后淋巴漏的发生。对于诊断时排出量大于17.2ml/kg/天的患者,建议早期应用全胃肠外营养。
    方法:三级,治疗研究(回顾性比较研究)。
    BACKGROUND: Lymphatic leakage is one of the postoperative complications of neuroblastoma. The purpose of this study is to summarize the clinical characteristics and risk factors of lymphatic leakage and try to find effective prevention and treatment measures.
    METHODS: A retrospective study included 186 children with abdominal neuroblastoma, including 32 children of lymphatic leakage and 154 children of non-lymphatic leakage. The clinical information, surgical data, postoperative abdominal drainage, treatment of lymphatic leakage and prognosis of the two groups were collected and analyzed.
    RESULTS: The incidence of lymphatic leakage in this cohort was 14% (32 children). Through univariate analysis of lymphatic leakage group and non-lymphatic leakage group, we found that lymphatic leakage increased the complications, prolonged the time of abdominal drainage and hospitalization, and delayed postoperative chemotherapy (p < 0.05). In this cohort, the median follow-up time was 46 (95% CI: 44-48) months. The follow-up data of 7 children were partially missing. 147 children survived, of which 23 had tumor recurrence (5 children recurred in the surgical area). 37 children died, of which 32 had tumor recurrence (9 children recurred in the operation area). In univariate analysis, there was no statistical difference in overall survival (p = 0.21) and event-free survival (p = 0.057) between lymphatic leakage group and non-lymphatic leakage group, while 3-year cumulative incidence of local progression was higher in lymphatic leakage group (p = 0.015). However, through multivariate analysis, we found that lymphatic leakage did not affect event-free survival, overall survival and cumulative incidence of local progression in children with neuroblastoma. Resection of 5 or more lymphatic regions was an independent risk factor for lymphatic leakage after neuroblastoma surgery. All 32 children with lymphatic leakage were cured by conservative treatment without surgery. Of these, 75% (24/32) children were cured by fat-free diet or observation, 25% (8/32) children were cured by total parenteral nutrition. The median drain output at diagnosis in total parenteral nutrition group was higher than that in non-total parenteral nutrition group (p < 0.001). The cut-off value was 17.2 ml/kg/day.
    CONCLUSIONS: Lymphatic leakage does not affect the prognosis of children with neuroblastoma, but long-term drain output caused by lymphatic leakage will still adversely affect postoperative complications and follow-up treatment, which requires attention and active treatment measures. More attention should be paid to the children with 5 or more lymphatic regions resection, and the injured lymphatic vessels should be actively found and ligated after tumor resection to reduce the postoperative lymphatic leakage. Early application of total parenteral nutrition is recommended for those who have drain output at diagnosis of greater than 17.2 ml/kg/day.
    METHODS: Level III, Treatment study (Retrospective comparative study).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    我们介绍了一名患者在骨盆手术后出现大量右胸腔积液的情况。不是胸外科手术.盆腔手术后淋巴漏入腹腔可引起大量胸腔积液,并发多孔隔膜综合征。
    We present the case of a patient who developed a massive right pleural effusion after pelvic surgery, not thoracic surgery. Lymphatic leakage into the abdominal cavity after pelvic surgery can cause massive pleural effusion when complicated with porous diaphragm syndrome.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:术后淋巴漏是腹膜后包块保守治疗无效的并发症。在这里,我们报告了一例腹膜后肿瘤切除术后发生的淋巴漏,并采用逆行经静脉胸导管栓塞治疗。
    方法:一名患有持续性腹痛的28岁男子被诊断患有一个10厘米大的腹膜后转移瘤和一个源自睾丸肿瘤的膈下淋巴结。高位睾丸切除术和新辅助化疗后,膈下淋巴结和腹膜后肿瘤与腹主动脉一起切除;后者使用假体移植重建。术后,患者出现乳糜胸。在包括禁食和生长抑素治疗的保守治疗后没有观察到改善。双侧腹股沟淋巴结顺行淋巴管造影无法确定渗漏部位。但通过逆行经静脉淋巴管造影发现.成功栓塞了渗漏部位。
    结论:本病例报告描述了腹膜后肿瘤和淋巴结切除后,逆行经静脉胸导管栓塞治疗乳糜胸的成功治疗。这种方法是乳糜胸的一种侵入性较小且更有效的治疗方式,当使用顺行方法无法确定泄漏点时,应在手术胸导管结扎之前考虑。
    BACKGROUND: Postoperative lymphatic leakage is a complication of ineffective conservative treatment for retroperitoneal mass. Herein, we report a case of lymphatic leakage that arose after retroperitoneal tumor resection and that was treated with retrograde transvenous thoracic duct embolization.
    METHODS: A 28-year-old man with persistent abdominal pain was diagnosed with a large retroperitoneal metastatic tumor measuring 10 cm and a subdiaphragmatic lymph node originating from a testicular tumor. After high orchidectomy and neoadjuvant chemotherapy, the subdiaphragmatic lymph node and retroperitoneal tumor were resected together with the abdominal aorta; the latter was reconstructed using a prosthetic graft. Postoperatively, the patient developed chylothorax. No improvement was observed after conservative treatment that included fasting and somatostatin therapy. The leakage site could not be identified using antegrade lymphangiography of the bilateral inguinal lymph nodes, but was detected using retrograde transvenous lymphangiography. The leakage site was successfully embolized.
    CONCLUSIONS: This case report describes successful treatment with retrograde transvenous thoracic duct embolization for chylothorax following resection of a retroperitoneal tumor and lymph node. This approach is a less invasive and more effective mode of treatment for chylothorax and should be considered before surgical thoracic duct ligation when the leakage point cannot be identified using the antegrade approach.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    蛋白丢失性肠病(PLE)是Fontan程序的严重并发症,由于肠蛋白丢失而导致全身并发症。由于淋巴压力升高而导致的肝十二指肠淋巴渗漏是此类并发症之一。我们介绍了一例小儿心脏移植患者,该患者出现难治性PLE症状,需要连续输注白蛋白,并表现出淋巴渗漏进入十二指肠。使用诊断性淋巴管造影和内窥镜检查,我们确定了受累区域,并采用乙醇胺注射的内镜硬化治疗成功.这种治疗可以停止淋巴液,并可能作为PLE相关的肝十二指肠淋巴漏的潜在干预措施。本病例强调了早期识别和及时干预放射学和内窥镜治疗以管理PLE及其相关并发症的重要性。
    Protein-losing enteropathy (PLE) is a severe complication of the Fontan procedure that leads to systemic complications owing to enteric protein loss. Hepatoduodenal lymphatic leakage resulting from increased lymphatic pressure is one such complication. We present the case of a pediatric heart transplant patient who experienced refractory PLE symptoms requiring serial albumin infusions and exhibited lymphatic leakage into the duodenum. Using diagnostic lymphangiography and endoscopy, we identified the affected area and treated it successfully with endoscopic sclerotherapy using ethanolamine injection. This treatment allowed for the cessation of lymphatic fluid and may serve as a potential intervention for PLE-associated hepatoduodenal lymphatic leakage. The present case highlights the importance of early recognition and timely intervention with radiology and endoscopic therapy to manage PLE and its associated complications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    手术引流管的持续淋巴渗漏是术后偶尔遇到的麻烦并发症。这项研究调查了肾脏或肝脏移植后的淋巴渗漏,比较传统置管引流术的疗效与微创淋巴干预。我们还讨论了考虑淋巴流动生理学的通路和治疗目标。
    在2018年9月至2020年9月期间,13例淋巴漏患者接受了微创淋巴介入治疗;11例接受了肾移植,两个人接受了肝脏移植.对照组包括10例肾移植术后淋巴漏患者,行导管引流。导管引流的治疗效果,淋巴干预,并对不同的栓塞靶点进行了比较。
    淋巴介入的技术成功率为100%,临床成功率为92%,治疗后第一天引流量减少82.9%。通过淋巴干预达到临床成功的持续时间为5.9天,保守导管引流33.9天。
    淋巴血管造影和栓塞是治疗肾或肝移植后持续性淋巴漏的微创和有效的方法。我们建议在上游淋巴管及时诊断和栓塞,以减少引流管滞留的持续时间。住院天数,和相关的合并症。
    Persistent lymphatic leakage from the surgical drain is a troubling complication occasionally encountered postoperatively. This study investigated lymphatic leaks after renal or liver transplantation, comparing the treatment efficacy of traditional catheter drainage vs. minimally invasive lymphatic interventions. We also discuss access and treatment targets considering the physiology of lymphatic flow.
    Between September 2018 and September 2020, 13 patients with lymphatic leakage were treated with minimally invasive lymphatic interventions; 11 had received a renal transplant, and two received a liver transplant. The control group included 10 patients with postrenal transplant lymphatic leakage treated with catheter drainage. The treatment efficacy of catheter drainage, lymphatic interventions, and different targets of embolization were compared.
    The technical success rate for lymphatic intervention was 100%, and the clinical success rate was 92%, with an 82.9% reduction in drain volume on the first day after treatment. The duration to reach clinical success was 5.9 days with lymphatic intervention, and 33.9 days with conservative catheter drainage.
    Lymphangiography and embolization are minimally invasive and efficient procedures for treating persistent lymphatic leaks after renal or liver transplantation. We suggest prompt diagnosis and embolization at upstream lymphatics to reduce the duration of drain retention, days of hospitalization, and associated comorbidities.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    Abdominal effusion due to hepatic lymphorrhea post-hepatectomy is an extremely rare and complex complication in clinical practice. No standard treatment method has been established for this condition to date. We report a case of complicated intra-abdominal lymphatic leakage in a patient following hepatectomy to treat hepatocellular carcinoma. The patient underwent percutaneous embolization of the hilar hepatic lymphatic system, combined with intensive medical treatment. Percutaneous embolization represents a safe and effective method that should be considered as a first-line treatment for this complication.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    BACKGROUND: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy.
    METHODS: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb).
    RESULTS: Among 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4-21 days). All cases resolved in a median 10 days (range, 3-56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289-8.360; P = 0.013), a decrease in hemoglobin level of ≥20 and < 30 g/L (OR, 6.175; 95%CI, 1.033-10.919; P = 0.046) or ≥ 30 g/L (OR, 8.467; 95%CI, 1.248-17.426; P = 0.029), and postoperative albumin level ≥ 30 and < 35 g/L (OR, 2.552; 95%CI, 1.112-5.857; P = 0.027) or < 30 g/L (OR, 5.517; 95%CI, 2.047-18.148; P = 0.012) were associated with PLL.
    CONCLUSIONS: Neoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    目的:观察铜绿假单胞菌-甘露糖敏感血凝素(PA-MSHA)治疗妇科恶性肿瘤淋巴结清扫术后难治性淋巴漏的可行性和疗效。
    方法:收集10例术后大量淋巴漏患者,其中患者对保守治疗无效。通过引流管或经阴道导管向盆腔或腹膜腔局部注射单剂量(2mL)PA-MSHA。记录引流量和副作用。
    结果:盆腔和主动脉旁淋巴结清扫术后难治性淋巴漏的发生率为2.44%(10/409)。所有10例患者(100%)均恢复迅速,并在72小时内出院。其中,1例患者(10%)出现发热,6例患者(60%)出现腹痛,其中一种是中度的,通过常规镇痛治疗可以缓解。在11(6-38)个月的随访时间内,没有观察到长期副作用。
    结论:单剂量局部注射PA-MSHA对于难治性术后淋巴漏似乎是一种可行且有效的治疗方法。
    OBJECTIVE: To observe the feasibility and efficacy of Pseudomonas aeruginosa-mannose sensitive hemagglutinin (PA-MSHA) in refractory lymphatic leakage following lymphadenectomy among patients with gynecological cancers.
    METHODS: Ten cases with post-operative massive lymphatic leakage were collected, in which patients failed to respond to conservative treatment. Topical PA-MSHA injection of a single dose (2mL) was performed through drainage tube or transvaginal catheter into pelvic or peritoneal cavity. Drainage volumes and side effects were recorded.
    RESULTS: The incidence of refractory lymphatic leakage following pelvic and para-aortic lymphadenectomy was 2.44% (10/409). All ten patients (100%) had quick recovery and were discharged within 72 hours. Among them, one patient (10%) experienced fever and six patients (60%) experienced abdominal pain, one of which was moderate and relieved by routine analgesic treatment. During 11 (6-38) months of follow-up time, no long-term side effect was observed.
    CONCLUSIONS: Topical injection of PA-MSHA of a single dose appears a feasible and effective treatment for refractory post-operative lymphatic leakage.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号